Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598938 | 0.89 | L3MBTL1 (0.53) | L3MBTL1CYP3A4TRPV1MAPK1USP2 | |
| SCHEMBL2101384 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CYP3A4TRPV1MAPK1USP2 | |
| SCHEMBL7460746 | 0.83 | L3MBTL1 (0.67) | L3MBTL1USP2GAATSHRMEN1 | |
| SCHEMBL17055837 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CYP3A4TRPV1MAPK1USP2 | |
| SCHEMBL7476434 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CYP3A4TRPV1MAPK1USP2 | |
| SCHEMBL7468675 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CYP3A4TRPV1MAPK1USP2 | |
| SCHEMBL18209180 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CYP3A4TRPV1MAPK1USP2 | |
| SCHEMBL20414554 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CYP3A4TRPV1MAPK1USP2 | |
| SCHEMBL13061281 | 0.81 | L3MBTL1 (0.60) | L3MBTL1CYP3A4TRPV1MAPK1USP2 | |
| SCHEMBL7468450 | 0.80 | L3MBTL1 (0.62) | L3MBTL1CYP3A4TRPV1MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | L3MBTL1 1176/4885CYP3A4 621/4885TRPV1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.